Loading...
Regen BioPharma, Inc.
RGBP•PNK
HealthcareBiotechnology
$0.04
$-0.02(-33.23%)
Regen BioPharma, Inc. (RGBP) Stock Overview
Explore Regen BioPharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.06
↓ 184.73%
EPS Growth
$-0.06
↓ 172.41%
Operating Margin
-155.54%
↑ 39.12%
ROE
18.27%
↓ 184.73%
Dividend Yield
0.00%
Analyst Recommendations data is not available for RGBPAnalyst Recommendations details for RGBP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
CEO
Dr. David Raymond Koos DBA, Ph.D.
Employees
1
Headquarters
4700 Spring Street, La Mesa, CA
Founded
2014